Antibiotic prescription patterns in the empiric therapy of severe sepsis: combination of antimicrobials with different mechanisms of action reduces mortality

[1]  C. Sprung,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock 2012 , 2013, Critical care medicine.

[2]  M. Levy,et al.  Cost-effectiveness of the Surviving Sepsis Campaign protocol for severe sepsis: a prospective nation-wide study in Spain , 2011, Intensive Care Medicine.

[3]  Anand Kumar,et al.  Optimizing antimicrobial therapy in sepsis and septic shock. , 2011, Critical care nursing clinics of North America.

[4]  A. Friedrich,et al.  Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. , 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[5]  S. Lapinsky,et al.  Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: A propensity-matched analysis* , 2010, Critical care medicine.

[6]  Anand Kumar,et al.  A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: A meta-analytic/meta-regression study , 2010, Critical care medicine.

[7]  Ricard Ferrer,et al.  Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. , 2009, American journal of respiratory and critical care medicine.

[8]  J. Rodríguez-Baño,et al.  [Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Spanish hospitals: 2nd multicenter study (GEIH-BLEE project, 2006)]. , 2009, Enfermedades infecciosas y microbiologia clinica.

[9]  Á. Pascual,et al.  Escherichia coli y Klebsiella pneumoniae productoras de betalactamasas de espectro extendido en hospitales españoles: segundo estudio multicéntrico (proyecto GEIH-BLEE 2006) , 2009 .

[10]  T. Welte,et al.  Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia. , 2009, The Journal of antimicrobial chemotherapy.

[11]  L. Baddour,et al.  β-Lactam and Fluoroquinolone Combination Antibiotic Therapy for Bacteremia Caused by Gram-Negative Bacilli , 2009, Antimicrobial Agents and Chemotherapy.

[12]  M. Levy,et al.  Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. , 2008, JAMA.

[13]  C. Roussos,et al.  Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  D. Cook,et al.  Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia* , 2008, Critical care medicine.

[15]  M. Levy,et al.  Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008 , 2007, Intensive Care Medicine.

[16]  L. Cosler,et al.  Comparison of β-Lactam and Macrolide Combination Therapy versus Fluoroquinolone Monotherapy in Hospitalized Veterans Affairs Patients with Community-Acquired Pneumonia , 2007, Antimicrobial Agents and Chemotherapy.

[17]  J. Rello,et al.  Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: An observational, multicenter study comparing monotherapy with combination antibiotic therapy* , 2007, Critical care medicine.

[18]  J. Rello,et al.  Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock* , 2007, Critical care medicine.

[19]  F. Gordo,et al.  Sepsis incidence and outcome: Contrasting the intensive care unit with the hospital ward* , 2007, Critical care medicine.

[20]  A. Ma,et al.  Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones. , 2007, Chest.

[21]  F. Daschner,et al.  Antibiotic use in two cohorts of German intensive care units. , 2006, The Journal of hospital infection.

[22]  D. Ledoux,et al.  Combination therapy versus monotherapy: a randomised pilot study on the evolution of inflammatory parameters after ventilator associated pneumonia [ISRCTN31976779] , 2006, Critical care.

[23]  G. Tillotson,et al.  The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia. , 2005, Chest.

[24]  M. Parnham.  Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections , 2005, Current opinion in infectious diseases.

[25]  D. Snydman,et al.  Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. , 2004, American journal of respiratory and critical care medicine.

[26]  J. Handelsman,et al.  Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. , 2004, The Lancet. Infectious diseases.

[27]  Leonard Leibovici,et al.  β lactam monotherapy versus β lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials , 2004, BMJ : British Medical Journal.

[28]  J. Garnacho-Montero,et al.  Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis* , 2003, Critical care medicine.

[29]  S. Ridley,et al.  Drugs in anaesthesia , 2003, Anaesthesia.

[30]  Stephan Harbarth,et al.  Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. , 2003, The American journal of medicine.

[31]  Corinne Alberti,et al.  Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study , 2002, Intensive Care Medicine.

[32]  G. Clermont,et al.  Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.

[33]  J. Carlet,et al.  Monotherapy with a Broad-Spectrum Beta-Lactam Is as Effective as Its Combination with an Aminoglycoside in Treatment of Severe Generalized Peritonitis: a Multicenter Randomized Controlled Trial , 2000, Antimicrobial Agents and Chemotherapy.

[34]  W. Knaus.  The APACHE III Prognostic System , 1992 .

[35]  W. Knaus,et al.  The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. , 1991, Chest.

[36]  E. Linko,et al.  [A medical intensive care unit]. , 1969, Nordisk medicin.

[37]  J. Rotschafer,et al.  Optimal use of fluoroquinolones in the intensive care unit setting. , 2011, Critical care clinics.

[38]  L. Cosler,et al.  Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. , 2007, Antimicrobial agents and chemotherapy.

[39]  L. Leibovici,et al.  Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. , 2004, BMJ.